- Tytuł:
- Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.
- Autorzy:
- Temat:
-
BLOOD coagulation factor VIII
EMICIZUMAB
HEMOPHILIACOST effectiveness
QUALITY-adjusted life years
PROSTATE-specific antigen - Źródło:
- European Journal of Haematology; Mar2023, Vol. 110 Issue 3, p262-270, 9p
- Terminy geograficzne:
- UNITED Kingdom
Czasopismo naukowe